Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company focused on nanoparticle-based cancer treatments, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management team, including CEO Laurent Levy and CFO Bart van Rhijn, will participate in a fireside chat on Tuesday, September 9th, 2025, at 9:00 am EDT. The presentation will be accessible via webcast on the company's investor relations website, with a replay available after the event.

PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at following conference:

H.C. Wainwright 27th Annual Global Investment Conference
Date: Tuesday, September 9th, 2025
Time: 9:00 am EDT / 3:00 pm CEST
Location: New York, NY
Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix & Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix
Webcast link: Click here

The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. The replay of the webcast will be available following the event.

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

Contacts

Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com	Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com
Media Relations
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr	Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com

 

Attachment

• 2025-09-02 -- NBTX -- Presenting @ HCW&Co -- FINAL.pdf

FAQ

When is Nanobiotix (NBTX) presenting at the H.C. Wainwright Conference 2025?

Nanobiotix will present on Tuesday, September 9th, 2025 at 9:00 am EDT / 3:00 pm CEST in New York, NY.

Who will be presenting at the H.C. Wainwright Conference for Nanobiotix?

Laurent Levy, Chief Executive Officer, and Bart van Rhijn, Chief Financial & Business Officer, will represent Nanobiotix at the conference.

How can investors access Nanobiotix's H.C. Wainwright Conference presentation?

The fireside chat will be available via live webcast on the events page of the Investors section of Nanobiotix's website, with a replay available after the event.

What is Nanobiotix's main business focus?

Nanobiotix is a late-clinical stage biotechnology company that pioneers nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases.